Many studies have reported that DXL, a first-line drug for the treatment of many types of cancer, exhibited low sensitivity partly due to activation of the NF-κB signaling pathway (Kani et al., 2013; Shao et al., 2013; Pan et al., 2016). Here, NFKB1 is linked to cancer.